Project Grant R50CA293895
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $182K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded $457,683 to The Children's Hospital of Philadelphia on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and optimize a macromolecular prodrug-based delivery strategy for the topoisomerase I inhibitor SN22 designed to overcome tumor defense mechanisms and suppress high-risk neuroblastoma, the most common and deadly solid tumor of childhood. The project targets...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $737,082 on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop bioinspired virus-like nanovaccines that boost chimeric antigen receptor (CAR) T cell and endogenous T cell responses against solid tumors with antigen heterogeneity. The recipient will develop an autologous tumor cell membrane-coated dual CAR and endogenous T cell boosting virus-like nanoparticle vaccine (DTVLP-VAX) to...
- The Department of the Army Medical Command awarded a $2,247,531 project grant to The Children's Hospital of Philadelphia through the Military Medical Research and Development program (CFDA 12.420) to conduct a comprehensive evaluation of immune function in patients receiving multimodal therapy for high-risk neuroblastoma. The four-year project beginning September 1, 2022 will apply basic, applied, and advanced biomedical research approaches to transform pediatric cancer care and investigate...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $738,666 on August 4, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer CD19 mimotopes for enhancing and repurposing CD19-CAR T cell therapy against hematological malignancies and solid tumors. The recipient will develop a high-affinity CD19 mimotope identified through yeast surface display screening to pair with existing CD19-CAR T products. The linear mimotope, a 10 amino acid peptide, is...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded The Trustees of The University of Pennsylvania $618,063 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop FLASH-CAR-T radioimmunotherapy for pediatric brain tumors. The project aims to advance immunomodulatory therapy for pediatric brain malignancies including medulloblastoma and glioma by combining FLASH proton beam radiation with...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $608,558 to the Research Institute at Nationwide Children's Hospital on April 2, 2026, under the Cancer Biology Research program (CFDA 93.396). The grant funds research to genetically and metabolically define high-risk neuroblastoma and develop effective therapeutic strategies. The project establishes and characterizes clinically relevant immunocompetent mouse models of...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $737,908 on August 12, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to support multi-modal data integration and functional screening to discover druggable targets in pediatric low-grade glioma. The research integrates imaging, bioinformatics, and cancer biology to identify novel molecular events across the genome, transcriptome, and epigenome in pediatric low-grade gliomas (PLGG), the most...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $263,656 on August 17, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research into novel mechanisms of acute myeloid leukemia (AML) resistance to chimeric antigen receptor T cell (CAR-T) therapy. The research aims to develop a detailed understanding of how altered STAT5 levels dictate poor outcomes for AML CAR-T therapies and to identify a combination therapy that selectively blocks AML...
- Federal Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $197,518 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective September 8, 2025, through August 31, 2030. This award supports the development of a Rare Tumor Clinical Research Specialist position focused on addressing critical barriers in clinical research for rare cancers, which collectively account for 25% of cancer deaths despite...
- The National Cancer Institute awarded Children's Research Institute $467,968 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to evaluate synergistic therapeutic effects of retinoic acid and proteasome inhibitors in neuroblastoma treatment. The funded research systematically evaluates combination therapy using proteasome inhibitors (bortezomib, carfilzomib, ixazomib) paired with isotretinoin (13-cis-retinoic acid) across genetically diverse neuroblastoma models that...